
## David M Shlaes

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2024890/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: Guidelines for the Prevention of Antimicrobial Resistance in Hospitals. Clinical Infectious Diseases, 1997, 25, 584-599.	2.9	625
2	New βâ€lactam–βâ€lactamase inhibitor combinations in clinical development. Annals of the New York Academy of Sciences, 2013, 1277, 105-114.	1.8	114
3	Class A $\hat{I}^2$ -lactamases $\hat{a} \in$ "enzyme-inhibitor interactions and resistance. , 1999, 83, 141-151.		111
4	Antibiotics—From There to Where?. Pathogens and Immunity, 2018, 3, 19.	1.4	51
5	Overcoming the challenges to developing new antibiotics. Current Opinion in Pharmacology, 2012, 12, 522-526.	1.7	30
6	Research and Development of Antibiotics: The Next Battleground. ACS Infectious Diseases, 2015, 1, 232-233.	1.8	20
7	The Economic Conundrum for Antibacterial Drugs. Antimicrobial Agents and Chemotherapy, 2019, 64, .	1.4	14
8	An update on tetracyclines. Current Opinion in Investigational Drugs, 2006, 7, 167-71.	2.3	12
9	The Perfect Storm. , 2010, , 1-7.		8
10	Antibacterial Drugs: The Last Frontier. ACS Infectious Diseases, 2020, 6, 1313-1314.	1.8	6
11	Innovation, Nontraditional Antibacterial Drugs, and Clinical Utility. ACS Infectious Diseases, 2021, 7, 2027-2028.	1.8	4
12	The Clinical Development of Antibacterial Drugs: A Guide for the Discovery Scientist. Topics in Medicinal Chemistry, 2017, , 149-163.	0.4	3
13	Personal View of the Antibiotic Value Proposition. ACS Infectious Diseases, 2020, 6, 1315-1316.	1.8	Ο